Earlier this week, Ascendis Pharma A/S reported Week 52 topline data from its Phase 2 COACH trial, showing that once-weekly TransCon CNP plus TransCon hGH in children with achondroplasia delivered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback